Sanofi, Regeneron broaden alliance to find their next Dupixent

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 01 Oct, 15:38 UTC

The deal carries a $1 billion upfront payment and tasks the two companies to develop long-acting antibody drugs that go after the same targets as their blockbuster anti-inflammation agent.